Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2011-04-05
2011-04-05
Landsman, Robert (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C424S078080
Reexamination Certificate
active
07919454
ABSTRACT:
The invention provides methods of screening agents, conjugates or conjugate moieties, linked or linkable to agents, for capacity to be transported as substrates through the PEPT2 transporter. The invention also provides methods of treatment involving delivery of agents that either alone, or as a result of linkage to a conjugate moiety, are substrates of the PEPT2 transporter. The invention also provides conjugates comprising a pharmaceutical agent which is linked to a conjugate moiety that is a substrate for a PEPT2 transporter.
REFERENCES:
patent: 4414148 (1983-11-01), Jansen et al.
patent: 4569789 (1986-02-01), Blattler et al.
patent: 4590071 (1986-05-01), Scannon et al.
patent: 4659839 (1987-04-01), Nicolotti et al.
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4680338 (1987-07-01), Sundoro
patent: 4699784 (1987-10-01), Shih et al.
patent: 5543158 (1996-08-01), Gref et al.
patent: 5578325 (1996-11-01), Domb et al.
patent: 5710018 (1998-01-01), Dantzig et al.
patent: 5723286 (1998-03-01), Dower et al.
patent: 2003/0017964 (2003-01-01), Zerangue et al.
patent: 188256 (1991-08-01), None
patent: WO 92/00091 (1992-01-01), None
patent: WO 92/09300 (1992-06-01), None
patent: WO 93/06121 (1993-04-01), None
patent: WO 94/08051 (1994-04-01), None
patent: WO 95/12608 (1995-05-01), None
patent: WO 95/30642 (1995-11-01), None
patent: WO 95/32184 (1995-11-01), None
patent: WO 95/35278 (1995-12-01), None
patent: WO 95/35503 (1995-12-01), None
patent: WO 01/20331 (2001-03-01), None
Sugawara M. et al. J Pharm Pharmacol. 44(12):968-72, Dec. 1992.
Tamai I et al. J. Pharm. Sci 87(12):1542-6, Dec. 1998.
Adibi, “The oligopeptide transporter (Pept-1) in human intestine: biology and function,”Gastroenterology1997, 113, 332-340.
Altschul et al., “Basic local alignment search tool,”J. Mol. Biol.1990, 215, 403-410.
Aramaki et al., “Stability of liposomes in vitro and their uptake by rat Peyer's patches following oral administration,”Pharm. Res.1993, 10(8), 1228-1231.
Boll et al., “Expression cloning and functional characterization of the kidney cortex high-affinity proton-coupled peptide transporter,”Proc. Natl. Acad. Sci. USA1996, 93, 284-289.
Bunin and Ellman, “A general and expedient method for the solid-phase synthesis of 1,4-benzodiazepine derivatives,”J Am Chem Soc1992, 114, 10997-10998.
Chen et al., “Polymerized liposomes as potential oral vaccine carriers: stability and bioavailability,”J Controlled Release1996, 42, 263-272.
Covitz et al., “Human dipeptide transporter, hPEPT1, stably transfected into Chinese hamster ovary cells,”Pharmaceutical Res1996, 13(11), 1631-1634.
Dantzig et al., “Association of intestinal peptide transport with a protein related to the cadherin superfamily,”Science1994, 264, 430-433.
Dantzig and Bergin, “Carrier-mediated uptake of cephalexin in human intestinal cells,”Biochemical Biophysical Res Commun1988, 155(2), 1082-1087.
Deshmuckh et al., “Can intact liposomes be absorbed in the gut,”Life Sci.1981, 28, 239-242.
Dieck at al., “The peptide transpoerter PepT2 is expressed in rat brain and mediates the accumulationof the fluorescent dipeptide derivative β-Ala-Lys-Nε-AMCA in Astrocytes,”Glia1999, 25(1), 10-20.
Dixon et al., “Absorption of amino penicillins from everted rat intestine,”J Physiol1977, 269, 549-559.
Dolle and Nelson, “Comprehensive survey of combinatorial library synthesis,” 1998.J Combinatorial Chemistry1999, 1(4), 235-282.
Doring et al., “Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications,”J Clin Invest1998, 101(12), 2761-2767.
Eggenweiler, “Linkers for solid-phase synthesis of small molecules: coupling and cleavage techniques,”Drug Discovery Today1998, 3(12), 552-560.
Fei et al., “Expression cloning of a mammalian proton-coupled oligopeptide transporter,”Nature1994, 368, 563-566.
Fei et al., “Preferential recognition of zwitterionic dipeptides as transportable substrates by the high-affinity peptide transporter PEPT2,”Biochimica Biophysica Acta1999, 1418, 344-351.
Ganapathy et al., “Differential recognition of β-lactam antibiotics by intestinal and renal peptide transporters, PEPT1 and PEPT2,”J Biol Chem1995, 270(43), 25672-25677.
Ganapathy et al., “Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT1 and PEPT2,”Biochimica Biophysica Acta1997, 1324, 296-308.
Geysen et al., “Strategies for epitope analysis using peptide synthesis,”J Immunol Meth1987, 102, 259-274.
Gonzalez et al., “An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines AsPc-1 and Capan-2,”Cancer Research1998, 58, 519-525.
Han et al., “CHO/PEPT1 cells over expressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs,”J Pharmaceutical Sciences1999, 88(3), 347-350.
Harlow and Lane, “Antibodies, A Laboratory Manual”, Cold Spring Harbor Publications, New York, 1988.
Henikoff and Henikoff, “Amino acid substitution matrices from protein blocks,”Proc. Natl. Acad. Sci. USA1992, 89, 10915-10919.
Houghten et al., “Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery,”Nature1991, 354(7), 84-86.
Inui et al., “Physiological and pharmacological implications of peptide transporters, PEPT1 and PEPT2,”Nephrol Dial Transplant2000, 15(suppl 6), 11-13.
Inui et al., “Transepithelial transport of oral cephalosporins by monolayers of intestinal epithelial cell line Caco-2: specific transport systems in apical and basolateral membranes,”J Pharmacology Experimental Therapeutics1992, 261(1), 195-201.
Iseki et al., “Comparison of transport characteristics of amino β-lactam antibiotics and dipeptides across rat intestinal brush border membrane,”J Pharm Pharmacol1989, 41, 628-632.
Iseki et al., “Intestinal absorption of several beta-lactam antibiotics. V. Effect of amino β-lactam analogues and dipeptides on the absorption of amino β-lactam antibiotics,”J Pharm Dyn1984, 7, 768-775.
Iseki et al., “Multiplicity of the H+dependent transport mechanism of dipeptide and anionic beta-lactam antibiotic ceftibuten in rat intestinal brush-border membrane,”J Pharmacol Exp Ther1999, 289(1), 66-71.
Karlin et al., “Applications and statistics for multiple high-scoring segments in molecular sequences,”Proc. Nat'l. Acad. Sci. USA1993, 90, 5873-5787.
Kitagawa et al., “Characteristics of uptake of cefroxadine by rabbit small intestinal brush border membrane vesicles,”Biol Pharm Bull1996, 19(2), 268-273.
Kunwar et al., “Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells,”J Neurosurgery1993, 79, 569-76.
Lam et al., “A new type of synthetic peptide library for identifying ligand-binding activity,”Nature1991, 354, 82-84.
Langer, “New methods of drug delivery,”Science1990, 249, 1527-1533.
Lebl et al., “Multiple release of equimolar amounts of peptides form a polymeric carrier using orthogonal linkage-cleavage chemistry,”Int J Pept Prot Res1993, 41, 201-203.
Lee et al., “Biopharmaceutics of transmucosal peptide and protein drug administration: role of transport mechanisms with a focus on the involvement of PEPT1,”J Controlled Release1999, 62, 129-140.
Leibach et al., “Peptide transporters in the intestine and the kidney,”Ann Rev Nutr1996, 16, 99-119.
Liang et al., “Human intestinal H+/peptide cotransporter,”Journal of Biological Chemistry1995, 270(12), 6456-6463.
Liu et al., “Molecular cloning of PEPT2, a new member of the H+/peptide cotranspo
Dias Tracy
Dower William J.
Zerangue Noa
Chang Lucy S.
Landsman Robert
Miller D. Byron
XenoPort, Inc.
LandOfFree
Methods of treating using conjugates transported by a PEPT2... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating using conjugates transported by a PEPT2..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating using conjugates transported by a PEPT2... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2686990